http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20030015393-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 |
| filingDate | 2001-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20030015393-A |
| titleOfInvention | Cyclic oxyguanidine pyrazinones as protease inhibitors |
| abstract | The present invention relates to cyclic oxyguanidine pyrazinone compounds comprising a compound of formula (I), a hydrate, a solvate or a pharmaceutically acceptable salt thereof. Compounds of the invention are potent inhibitors of proteases, in particular trypsin-like serine proteases such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Some of the compounds of the present invention exhibit antithrombotic activity through direct and selective inhibition of thrombin. Also disclosed are compositions that inhibit platelet loss, platelet aggregation, fibrin formation, thrombus formation, and clot formation. The compounds of the present invention may also be embedded in, or physically embedded in, materials used in the manufacture of devices used for blood collection, blood circulation, and blood storage, such as catheters, hemodialysis, blood collection syringes and tubes, blood lines and stents. It can also be used as anticoagulant in combination. In addition, the compounds of the present invention can be detectably labeled and used for in vivo imaging of thrombi.n n n Formula In n n n n n n n Wherein R 3 , R 4 , R 5 , W and A are as described in the specification. |
| priorityDate | 2000-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 543.